Haleon (NYSE:HLN) Stock Bumped Down to “Strong Sell” by Zacks Research

Zacks Research downgraded shares of Haleon (NYSE:HLN) from a hold rating to a strong sell rating in a report released on Thursday morning,Zacks reports.

A number of other brokerages have also recently commented on HLN. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Friday, September 25th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Wednesday, September 9th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Haleon in a report on Tuesday, August 11th. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a research note on Wednesday, September 23rd. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.90.

Haleon Price Performance

Shares of NYSE:HLN opened at $10.29 on Thursday. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $45.30 billion, a PE ratio of 26.37, a P/E/G ratio of 2.34 and a beta of 0.14. Haleon has a twelve month low of $8.65 and a twelve month high of $11.28. The company has a 50-day moving average price of $9.56 and a two-hundred day moving average price of $9.51.

Haleon Cuts Dividend

The company also recently declared a dividend, which was paid on Thursday, September 17th. Investors of record on Friday, August 14th were issued a dividend of $0.0642 per share. The ex-dividend date was Friday, August 14th. This represents a yield of 132.0%. This is a decrease from Haleon’s previous dividend of $0.1307. Haleon’s dividend payout ratio (DPR) is currently 30.77%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Parkside Financial Bank & Trust increased its holdings in shares of Haleon by 20.4% during the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after acquiring an additional 1,055 shares in the last quarter. Personal CFO Solutions LLC boosted its stake in Haleon by 11.5% in the 1st quarter. Personal CFO Solutions LLC now owns 15,673 shares of the company’s stock worth $157,000 after purchasing an additional 1,620 shares in the last quarter. Sterling Capital Management LLC boosted its stake in Haleon by 1.9% in the 3rd quarter. Sterling Capital Management LLC now owns 88,039 shares of the company’s stock worth $792,000 after purchasing an additional 1,624 shares in the last quarter. Diversify Advisory Services LLC grew its position in Haleon by 7.7% during the 3rd quarter. Diversify Advisory Services LLC now owns 24,023 shares of the company’s stock valued at $239,000 after purchasing an additional 1,711 shares during the last quarter. Finally, Allen Capital Group LLC grew its position in Haleon by 14.5% during the 1st quarter. Allen Capital Group LLC now owns 13,628 shares of the company’s stock valued at $136,000 after purchasing an additional 1,729 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.